



9 November 2021

*The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.*

**Nuformix plc**  
**(“Nuformix” or the “Company”)**

**Directorate change**

**Nuformix plc** (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that Dr Alastair Riddell, currently Non-Executive Chairman, will assume the role of Executive Chairman with effect from 1 December 2021.

**Enquiries:**

**Nuformix plc**

Dr Alastair Riddell, Non-Executive Chairman  
Dr Anne Brindley, CEO

via Walbrook

**Allenby Capital Limited**

Nick Athanas / George Payne (Corporate Finance)  
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking)

+44 (0) 20 3328 5656

**Walbrook PR**

Anna Dunphy / Phillip Marriage

[nuformix@walbrookpr.com](mailto:nuformix@walbrookpr.com) or +44 (0)20 7933 8780

Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082

**About Nuformix**

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit [www.nuformix.com](http://www.nuformix.com).